References
- Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Eurals Consortium. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler 2009;10:310–23.
- Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology 2003;22:217–28.
- Lin FC, Tsai CP, Kuang-Wu Lee J, Wu MT, Tzu-Chi Lee C. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol 2015;72:40–8.
- Kawajiri M, Mogi M, Higaki N, Tateishi T, Ohyagi Y, Horiuchi M, et al. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis Acta Neurol Scand 2009;119:341–4.
- Santalucia P, Baviera M, Cortesi L, Tettamanti M, Marzona I, Nobili A, et al. Epidemiologic Trends in Hospitalized Ischemic Stroke from 2002 to 2010: Results from a Large Italian Population-Based Study. J Stroke Cerebrovasc Dis 2015;24:1917–23.
- Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G; SLALOM Group. Incidence of ALS in Lombardy, Italy. Neurology 2007;8:141–5.
- Armon C, Kurland LT, O’Brien PC, Mulder DW. Antecedent medical diseases in patients with amyotrophic lateral sclerosis. A population-based case-controlled study in Rochester, Minn, 1925 through 1987. Arch Neurol 1991;48:283–6.
- Körner S, Kollewe K, Ilsemann J, Müller-Heine A, Dengler R, Krampfl K, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol 2013;20:647–54.
- Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253–9.
- Grimmsmann T, Himmel W. Relation between Defined Daily Doses (DDD) and prescribed daily doses: a 3-month analysis of outpatient data from a statutory health insurance company] (in German). Gesundheitswesen 2010;72:412–18.
- Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147–57.
- Wang H, O’Reilly EJ, Weisskopf MG, Logroscino G, McCullough ML, Schatzkin A, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol 2011;173:595–602.
- Freedman DM, Kuncl RW, Weinstein SJ, Malila N, Virtamo J, Albanes D. Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:246–51.
- Wu S-J, Chang Y-H, Wei I-L, Kao M-D, Lin Y-C, Pan W-H. Intake levels and major food sources of energy and nutrients in the Taiwanese elderly. Asia Pac J Clin Nutr 2005;14:211–20.
- Mantle D, Patel VB, Why HJF, Ahmed S, Rahman I, MacNee W, et al. Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension. Clin Chim Acta 2000;299:1–10.